Targeted cisplatin
WebJan 26, 2024 · The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin elicited a significant improvement in overall survival (OS) vs gemcitabine and cisplatin … WebKeywords: cisplatin‐resistance, nano‐zinc carriers, non‐small cell lung cancer, small interfering RNA, targeted therapy Abstract The ligands are combined with nano‐zinc …
Targeted cisplatin
Did you know?
WebApr 13, 2024 · Researchers at the University Hospital Bonn (UKB) have now been able to elucidate a mechanism underlying cisplatin resistance in testicular cancer. Using CRISPR … WebSep 18, 2024 · National Center for Biotechnology Information
WebAug 28, 2024 · Targeting androgen-receptor (AR) signaling in metastatic bladder cancer with enzalutamide (Xtandi) in combination with gemcitabine and cisplatin is considered a safe and tolerable regimen, based on the results of a phase I/Ib trial. 1. The dose-escalation phase included patients with AR-positive and AR-negative disease and followed the 3+3 … WebJan 13, 2011 · Here we report that targeted delivery of cisplatin in the form of a prodrug 1 using a NP delivery system can markedly improve its tolerability and efficacy in vivo. Our studies have broad implications for cancer therapy given the relatively ubiquitous use of … Proceedings of the National Academy of Sciences of the United States of ...
WebKeywords: cisplatin‐resistance, nano‐zinc carriers, non‐small cell lung cancer, small interfering RNA, targeted therapy Abstract The ligands are combined with nano‐zinc hydroxide carriers to guide aptamer and siUSP14 to specifically bind to the surface of DDP‐resistant A549/DDP cells. WebFeb 3, 2024 · Introduction. In recent decades, cisplatin (cis-diamminedichloroplatinum II, or DDP), a classic platinum-based antitumor agent that exerts significant genotoxicity, has been extensively applied in clinical treatment and laboratory research 1.Because of its broad spectrum of anticancer activity, cisplatin is used to treat various solid tumors such as …
WebTargeted nanomedicine shows great promise in delivering cisplatin for maximizing efficacy while minimizing off-target toxicity. This article surveyed the recent progress and challenges of targeted nanomedicine in managing resistance and toxicity of cisplatin in both fundamental and clinical aspects. Particularly, we focused on three major ...
WebSep 2, 2024 · As we know that cisplatin is a first-line therapeutic drug for lung cancer, the applicability of cisplatin to the targeted site needs therapeutic efficiency with nil side … date of registration of a companyWebThe structure of the [Pd 2 L 4 ⊃(cisplatin) 2](BF 4) 4 host–guest adduct has been confirmed by 1 H NMR spectroscopy, HR-ESMS and X-ray crystallography. Additionally we have demonstrated that the cage–cisplatin host–guest adduct can be quantatively disassembled upon the addition of a competing ligand , releasing the cisplatin guest. date of record and ex dividend dateWebTargeted nanomedicine shows great promise in delivering cisplatin for maximizing efficacy while minimizing off-target toxicity. This article surveyed the recent progress and … date of red scareWebMay 1, 2024 · Abstract. Since its license in 1978, cisplatin has proved to be one of the most successful chemotherapeutic agents in the world. However, two acute challenges facing … date of registration meaningWebThe discrepancy of surface receptors on cancerous and non-cancerous cells has been regarded as the mainstay of cancer-targeted therapy. However, due to the heterogeneity of tumor cells and the insufficient levels of receptors on the tumor cell surface, the success of cancer cell-targeted therapies is largely Bioorthogonal and click chemistry: Celebrating … date of receipt of goodsWebThe cellular uptake of cisplatin and its targets. Reprinted with permission. 1 As seen in Figure 1, once inside the cell, cisplatin has a number of possible targets: DNA; RNA; sulfur-containing enzymes such as metallothionein and glutathione; and mitochondria. bizhub 165e driver download for windows 10WebMethods. Twenty-five patients diagnosed with stage III/IV pyriform sinus squamous cell carcinoma treated with supradose, intra-arterial targeted cisplatin, and concomitant radiotherapy were analyzed for response rates, survival, pattern of failure, and function of the preserved organs. date of referendum to join eec